what drives us

At Chimerix, we’re committed to driving the development of groundbreaking medicines designed to protect immunocompromised patients from potentially deadly viral infections.

The Need for Antiviral Protection

  • 70K
    Number of hematopoietic cell transplants (HCT) performed each year worldwide1
  • 65%
    Percentage of cytomegalovirus (CMV)-related DNA viral infections that led to hospital readmission after HCT2
  • 0
    Number of approved therapies for the prevention of CMV in HCT recipients3
  • 8-18%
    Percentage of kidney transplant patients who have CMV infection4

development pipeline

Our lead product candidate, brincidofovir, has the potential to become the first antiviral for the prevention of CMV infections.
SURPASS and SUSTAIN Clinical Trials
Phase 3 trials evaluating brincidofovir for the prevention of CMV in kidney transplant recipients.

disease areas of expertise

Cytomegalovirus (CMV)

Cytomegalovirus (CMV) is a member of the herpesvirus family and remains a significant cause of viral infections in transplant recipients.


Adenovirus, which causes the common cold in people with healthy immune systems, can lead to life-threatening infections in immunocompromised people.


Though smallpox has been officially eradicated, it remains a threat in cases of bio error or as a potential bioterror weapon.